Aerocrine AB announced that Health Care Service Corp. will begin covering FeNO testing for asthma diagnosis and management effective April 1. According to a release, Aerocrine has received ...

This case study has been carried out by Carol Stonham MBE, a Medical Advisory Board member. Carol has worked as a registered nurse since 1986, shifting from acute hospital care to primary care by 1990 ...

Nov. 17, 2021 – In its latest clinical practice guideline on evaluation and treatment of asthma, an American Thoracic Society expert guidelines panel has addressed the use of fractional exhaled nitric ...

The Fractional Exhaled Nitric Oxide (FeNO) test has long been part of clinical guidelines and was a key element in the previous asthma care recommendations from the National Institute for Health and ...

Aerocrine AB has announced that Health Care Service Corp. will begin covering FeNO testing for asthma diagnosis and management effective April 1. In a release, the Company said that it has received ...

Please provide your email address to receive an email when new articles are posted on . Fractional exhaled nitric oxide testing is beneficial and is recommended in addition to usual care in patients ...

IS LUNG HEALTH DAY, THOUGH MANY OF US TAKE BREATHING FOR GRANTED, MILLIONS OF PEOPLE STRUGGLE GETTING ENOUGH AIR DUE TO ASTHMA CONDITION THAT CAN BE DEADLY. AN ESTIMATED 262 MILLION PEOPLE WORLDWIDE ...

Please provide your email address to receive an email when new articles are posted on . Sex-based stratification with different cutoff values could improve diagnoses, Xue Zhang, PhD, of the department ...

Rochester, MN, December 21, 2017 - Although about 24 million Americans are diagnosed with asthma every year, there is no single test that can diagnose the disease. Common symptoms, such as shortness ...

In recent years, non-invasive measurement and monitoring of the fraction of exhaled nitric oxide (FeNO) in exhaled breath has become established as the biomarker of asthma. The sensor based technology ...

Oxford, UK - 24 March 2026: NIOX Group plc (AIM: NIOX), a medical device company focused on point-of-care FeNO testing for the diagnosis, monitoring and management of asthma and COPD, today announces ...